Radiochemical studies relevant to the no-carrier-added production of <sup>61,64</sup>Cu at a cyclotron

Sadeghi, Mahdi; Amiri, Mohammad; Roshanfarzad, P.; Avila, M.J.; Tenreiro, Claudio

doi:10.1524/ract.2008.1504

Cited by 15 publications

(24 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It gives the product in high yield and with high specific radioactivity. Although it involves the use of rather expensive highly enriched target material, generally electroplated on a Au backing, the technology has been fully developed 20,[37][38][39][40][41][42][43][44][45] by utilizing this route for the production of 64 Cu over the energy range of E p = 12 → 8 MeV. Batch yields of about 40 GBq 64 Cu are achieved, and the enriched target material 64 Ni is efficiently recovered.…”

Section: Cu (T ½ = 127 H)mentioning

confidence: 99%

Development of novel radionuclides for medical applications

Qaim

Spahn

2017

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Medical radionuclide production technology is well established. There is, however, a constant need for further development of radionuclides. The present efforts are mainly devoted to nonstandard positron emitters (eg, Cu, Y, I, and Se) and novel therapeutic radionuclides emitting low-range β particles (eg, Cu and Re), conversion or Auger electrons (eg, Sn and Br), and α particles (eg, Ac). A brief account of various aspects of development work (ie, nuclear data, targetry, chemical processing, and quality control) is given. For each radionuclide under consideration, the status of technology for clinical scale production is discussed. The increasing need of intermediate-energy multiple-particle accelerating cyclotrons is pointed out.

show abstract

Section: Cu (T ½ = 127 H)mentioning

confidence: 99%

Development of novel radionuclides for medical applications

Qaim

Spahn

2017

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

“…Tritium is generally available as tritium gas or tritiated water, 14 C as 14 CO 2 or Ba 14 CO 3 , and 125 I as 125 I − . In addition to the three major soft β − emitting radionuclides mentioned above, two other soft β − emitting nuclides, namely 33 P (T 1/2 = 25.3 d; E β − = 248 keV) and 35 S (T 1/2 = 87.5 d; E β − = 167 keV), also find some limited application involving in vitro investigations. Both are produced in the no-carrier-added form in a high fast flux nuclear reactor, the former via the 33 S(n, p) 33 P reaction on isotopically enriched 33 S and the latter through the 35 Cl(n, p) 35 S reaction on a KCl target [cf .…”

Section: Soft β − Emitters For In Vitro Studiesmentioning

confidence: 99%

“…Nonetheless, the technology has been well developed [30][31][32][33][34][35] for production of 64 Cu in batches of about 40 GBq and recovery of the enriched target material. The separation of 64 Cu is generally done via anion-exchange chromatography.…”

Section: Novel Positron Emittersmentioning

confidence: 99%

The present and future of medical radionuclide production

Qaim

2012

Radiochimica Acta

103

View full text Add to dashboard Cite

Reactor and cyclotron production of medical radionuclides / γ -ray emitters for SPECT / Positron emitters for PET / Corpuscular radiation emitters for internal radiotherapy / Low and intermediate energy nuclear reactions / Radionuclide generators / Future directionsSummary. Medical radionuclide production technology is well established. Both reactors and cyclotrons are utilized for production; the positron emitters, however, are produced exclusively using cyclotrons. A brief survey of the production methods of most commonly used diagnostic and therapeutic radionuclides is given. The emerging radionuclides are considered in more detail. They comprise novel positron emitters and therapeutic radionuclides emitting low-range electrons and α-particles. The possible alternative production routes of a few established radionuclides, like 68 Ga and 99m Tc, are discussed. The status of standardisation of production data of the commonly used as well as of some emerging radionuclides is briefly mentioned. Some notions on anticipated future trends in the production and application of radionuclides are considered.

show abstract

“…The production route 64 Ni( p, n) 64 Cu, originally suggested by the Jülich group [14], has been further developed in several other laboratories [cf . [45][46][47][48][49][50]. In a recent work sophisticated targetry calculations have been done [50].…”

Section: Production Using Low-energy Reactionsmentioning

confidence: 99%

Development of novel positron emitters for medical applications: nuclear and radiochemical aspects

Qaim¹

2011

Ract

View full text Add to dashboard Cite

In molecular imaging, the importance of novel longer lived positron emitters, also termed as non-standard or innovative PET radionuclides, has been constantly increasing, especially because they allow studies on slow metabolic processes and in some cases furnish the possibility of quantification of radiation dose in internal radiotherapy. Considerable efforts have been invested worldwide and about 25 positron emitters have been developed. Those efforts relate to interdisciplinary studies dealing with basic nuclear data, high current charged particle irradiation, efficient radiochemical separation and quality control of the desired radionuclide, and recovery of the enriched target material for reuse. In this review all those aspects are briefly discussed, with particular reference to three radionuclides, namely 64 Cu, 124 I and 86 Y, which are presently in great demand. For each radionuclide several nuclear routes were investigated but the ( p, n) reaction on an enriched target isotope was found to be the best for use at a small-sized cyclotron. Some other positron emitting radionuclides, such as 55 Co, 76 Br, 89 Zr, 82m Rb, 94m Tc, 120 I, etc., were also produced via the low-energy ( p, n), ( p, α) or (d, n) reaction. On the other hand, the production of radionuclides 52 Fe, 73 Se, 83 Sr, etc. using intermediate energy ( p, xn) or (d, xn) reactions needs special consideration, the nuclear data and chemical processing methods being of key importance. In a few special cases, a high intensity 3 He-or α-particle beam could be an added advantage. The production of some potentially interesting positron emitters via generator systems, for example 44 Ti/ 44 Sc, 72 Se/ 72 As and 140 Nd/ 140 Pr is considered. The significance of new generation high power accelerators is briefly discussed.

show abstract

Radiochemical studies relevant to the no-carrier-added production of ^61,64Cu at a cyclotron

Cited by 15 publications

References 13 publications

Development of novel radionuclides for medical applications

Development of novel radionuclides for medical applications

The present and future of medical radionuclide production

Development of novel positron emitters for medical applications: nuclear and radiochemical aspects

Contact Info

Product

Resources

About

Radiochemical studies relevant to the no-carrier-added production of 61,64Cu at a cyclotron

Cited by 15 publications

References 13 publications

Development of novel radionuclides for medical applications

Development of novel radionuclides for medical applications

The present and future of medical radionuclide production

Development of novel positron emitters for medical applications: nuclear and radiochemical aspects

Contact Info

Product

Resources

About

Radiochemical studies relevant to the no-carrier-added production of ^61,64Cu at a cyclotron